Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00431-23Source: DataRank Database

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin is a research paper published in Antimicrobial Agents and Chemotherapy (2023). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.51)OA: greenTopics (44)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Kamunkhwala Gausi ORCID,Ruth Nabisere,Joseph Musaazi ORCID,Allan Buzibye ORCID,Denis Omali ORCID

Live enrichment

PubMed:37850737 PMC:PMC10649026 OpenAlex:https://openalex.org/W4387729544

EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership

Grant: TMA2016CDF-1580

EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership

Grant: RIA2016MC-1606-VirTUAL

HHS | NIH | NIH Office of the Director

Grant: K24AI150349

FIC NIH HHS

Grant: D43 TW009771

European & Developing Countries Clinical Trials Partnership (EDCTP)

Grant: RIA2016MC-1606

Scottish Funding Council

FWCI

0.51

Citation Percentile

0.6%

Influential Citations

Citation Trend

2024

2025

2026

greenLicense: https://doi.org/10.1128/ASMCopyrightv2

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10649026/pdf/aac.00431-23.pdf

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649026

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10649026/pdf/aac.00431-23.pdf

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.00431-23

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10649026

Fields of Study

HIV/AIDS drug development and treatmentPharmacological Effects and Toxicity StudiesDrug Transport and Resistance MechanismsMedicineAdultHumansRifampinAntibiotics, AntitubercularUgandaTuberculosisBenzoxazinesHIV InfectionsCyclopropanesAnti-HIV AgentsAntitubercular Agents

MeSH Terms

AdultAntibiotics, AntitubercularAntitubercular AgentsCyclopropanesHumansRifampinTuberculosisUgandaHIV InfectionsAnti-HIV AgentsBenzoxazines

Keywords

RifampicinEfavirenzDolutegravirPharmacokineticsMedicineBioavailabilityTuberculosisPharmacologyDrugTb treatmentHuman immunodeficiency virus (HIV)Internal medicineAntiretroviral therapyVirologyViral loadPathologyHigh-doseTop-up Capsule

Sustainable Development Goals

SDG 0: Good health and well-being